Celia Oreja-Guevara - European Medicines Agency

Curriculum Vitae
PERSONAL INFORMATION
Celia Oreja-Guevara
WORK EXPERIENCE
May 2012–Present
Clinical Research Coordinator, Neurology
Hospital Clinico San Carlos, Madrid, (Spain)
December 2006–May 2012
Head of Multiple Sclerosis Unit, Neurology
Hospital Universitario La Paz, Madrid, (Spain)
January 2004–November 2006
Coordinator of the Neurology Department
Hospital de Fuenlabrada, Neurology, (Spain)
2003–2003
Senior Neurologist / Research Fellow
Department of Neurology, University of Duesseldorf (Germany) and Neurobiology, Bochum,
(Germany)
2002–2002
Senior Neurologist in Neuroimaging
Department of Neurology, University Hospital San Raffaele, Milan , (Italy)
2001–2001
Senior Neurologist / Research Fellow
Department of Neurology, University of Duesseldorf (Germany) and Neurobiology, Bochum,
(Germany)
1997–2001
Senior Neurologist
Department of Neurology, University of Bochum, (Germany)
1992–1997
Resident in Neurology
University Hospital Bergmannsheil, Augustahospital Isselburg, (Germany)
October 1990–March 1992
Research Fellow in Neuroimmunology, Resident in Neurology
Department of Neuroimmunology, Max-Planck-Institut für Neurobiologie, Munich-Martinsried,
(Germany)
EDUCATION AND TRAINING
September 1984–July 1990
Medical Doctor
Medical School, University Complutense of Madrid, (Spain)
October 1990–March 1992
PhD
University of Ludwig-Maximilian and Max-Planck Institut für Neurobiologie, Munich, (Germany)
Thesis: Interaction of T lymphocytes with cerebral endothelial cells in EAE
1994–1994
General Medicine (GP), Madrid
(Spain)
16/11/14
© European Union, 2002-2014 | http://europass.cedefop.europa.eu
Page 1 / 8
Curriculum Vitae
1992–1997
Celia Oreja-Guevara
Specialist of Neurology
(Germany)
1997–2000
Bachelor Clinical examinations of laboratory in neurology
University Hospital Bergmannsheil , Bochum, (Germany)
2004–2005
Master Management of Integrated Health Systems (Executive
Education)
ESADE University, Madrid, (Spain)
2010–2011
MS Master in Neuroimmunology
Autónoma University of Barcelona, (Spain)
ADDITIONAL INFORMATION
Expertise
Research areas
Clinical and neuroimaging correlations in multiple sclerosis.
Non-conventional Techniques of Magnetic Resonance in multiple sclerosis
Utility of optical coherence tomography in MS
Changes in cytokines and regulatory cells in different MS treatments
Principal Investigator in many MS clinical trials
Neurogenesis of demyelinating diseases
Publications
Spelman T, Gray O, Trojano M, Petersen T, Izquierdo G, Lugaresi A, Hupperts R,
Bergamaschi R, Duquette P, Grammond P, Giuliani G, Boz C, Verheul F,
Oreja-Guevara C, et al Seasonal variation of relapse rate in multiple sclerosis is
latitude dependent. Ann Neurol. 2014 Oct 4.
Calabresi PA, Kieseier BC, Arnold DL, Balcer LJ, Boyko A, Pelletier J, Liu S,
Zhu Y, Seddighzadeh A, Hung S, Deykin A; ADVANCE Study Investigators. Pegylated
interferon β-1a for relapsing-remitting multiple sclerosis (ADVANCE): a
randomised, phase 3, double-blind study. Lancet Neurol. 2014 Jul;13(7):657-65.
Oreja-Guevara C, Wiendl H, Kieseier BC, Airas L . Specific aspects of modern life for people with
multiple sclerosis: considerations for the practitioner. Ther Adv Neurol Disord. . Ther Adv Neurol
Disord. 2014Mar;7(2):137-49
Kalincik T, Buzzard K, Jokubaitis V, Trojano M, Duquette P, Izquierdo G,
Girard M, Lugaresi A, Grammond P, Grand'Maison F, Oreja-Guevara C et al; MSBase Study Group.
Risk of relapse phenotype
recurrence in multiple sclerosis. Mult Scler. 2014 Oct;20(11):1511-22..
De Stefano N, Airas L, Grigoriadis N, Mattle HP, O'Riordan J, Oreja-Guevara C,
Sellebjerg F, Stankoff B, Walczak A, Wiendl H, Kieseier BC. Clinical relevance of
brain volume measures in multiple sclerosis. CNS Drugs. 2014 Feb;28(2):147-56.
Fernández Ó, Rodríguez-Antigüedad A, Oreja-Guevara C, Garcia-Garcia M,
Montalban X; en representación de los investigadores del Registro Español de
Gilenya. [Usefulness of electronic drug registers: Spanish register of patients
treated with fingolimod (Gilenya ®)]. Rev Neurol. 2014 Jan 16;58(2):77-83.
Fernández O, García-Merino JA, Arroyo R, Alvarez-Cermeño JC, Izquierdo G, Saiz
16/11/14
© European Union, 2002-2014 | http://europass.cedefop.europa.eu
Page 2 / 8
Curriculum Vitae
Celia Oreja-Guevara
A, Olascoaga J, Rodríguez-Antigüedad A, Prieto JM, Oreja-Guevara C, Hernández MA,
Moral E, Meca J, Montalbán X. Spanish consensus on the use of natalizumab
(Tysabri(®))-2013. Neurologia. 2013 Dec 18.
Koehler J, Amato MP, Oreja-Guevara C, Lycke J. Clinical case reviews in
multiple sclerosis spasticity: experiences from around Europe. Expert Rev
Neurother. 2013 Dec;13(12 Suppl):61-6.
Gold R, Oreja-Guevara C. Advances in the management of multiple sclerosis
spasticity: multiple sclerosis spasticity guidelines. Expert Rev Neurother. 2013
Dec;13(12 Suppl):55-9.
Oreja-Guevara C, Montalban X, de Andres C, Casanova-Estruch B, Munoz-Garcia D, Garcia I,
Fernandez O. [Consensus document on spasticity in patients with multiple sclerosis]. Rev Neurol.
2013 Oct 16;57(8):359-73.
Noval S, Oreja-Guevara C, Contreras I. Monitoring neuromyelitis optica activity. Expert Rev Neurother.
2013 Sep;13(9):989-99.
Brück W, Gold R, Lund BT, Oreja-Guevara C, Prat A, Spencer CM, Steinman L, Tintoré M, Vollmer
TL, Weber MS, Weiner LP, Ziemssen T, Zamvil SS. Therapeutic Decisions in Multiple Sclerosis:
Moving Beyond Efficacy. JAMA Neurol. 2013 Oct;70(10):1315-24
García-Merino A, Fernández O, Montalbán X, de Andrés C, Oreja-Guevara C, Rodríguez-Antigüedad
A, Arbizu T. Consensus Statement on medication use in multiple sclerosis by the Spanish Society of
Neurology's study group for demyelinating diseases. Neurologia. 2013 Jul-Aug;28(6):375-8
Kalincik T, Vivek V, Jokubaitis V, Lechner-Scott J, Trojano M, Izquierdo G,
Lugaresi A, Grand'maison F, Hupperts R, Oreja-Guevara C, et al. on behalf of the MSBase Study
Group. Sex as a determinant of relapse incidence and progressive course of multiple sclerosis. Brain.
2013 Oct 18.
Hughes SE, Spelman T, Gray OM, Boz C, Trojano M, Lugaresi A, Izquierdo G,
Duquette P, Girard M, Grand'maison F, Grammond P, Oreja-Guevara C, Hupperts R,
Et al. for the MSBase study group. Predictors and dynamics of postpartum
relapses in women with multiple sclerosis. Mult Scler. 2013 Oct 9
Fernandez O, Arnal-Garcia C, Arroyo-Gonzalez R, Brieva L, Calles-Hernandez MC,
Casanova-Estruch B, Comabella M, de Las Heras V, Garcia-Merino JA,
Hernandez-Perez MA, Izquierdo G, Matas E, Meca-Lallana JE, Mendibe-Bilbao MM,
Munoz-Garcia D, Olascoaga J, Oreja-Guevara C, Prieto JM et al. Review of the novelties presented
at the 28th Congress of the European Committee for Treatment and Research in Multiple Sclerosis
(ECTRIMS) (III). Rev Neurol. 2013 Oct 1;57(7):317-329.
Fernandez O, Arnal-Garcia C, Arroyo-Gonzalez R, Brieva L, Calles-Hernandez MC,
Casanova-Estruch B, Comabella M, de Las Heras V, Garcia-Merino JA,
Hernandez-Perez MA, Izquierdo G, Matas E, Meca-Lallana JE, Mendibe-Bilbao MM,
Munoz-Garcia D, Olascoaga J, Oreja-Guevara C, et al. Grupo Post-Ectrims GP. Review of the
novelties presented at the 28th Congress of the uropean Committee for Treatment and Research in
Multiple Sclerosis (ECTRIMS) II). Rev Neurol. 2013 Sep 16;57(6):269-81.
Fernández Ó, Arnal-García C, Arroyo-González R, Brieva L, Calles-Hernández MC,
Casanova-Estruch B, Comabella M, de Las Heras V, García-Merino JA,
Hernández-Pérez MA, Izquierdo G, Matas E, Meca-Lallana JE, Mendibe-Bilbao Mdel M,
Muñoz-García D, Olascoaga J, Oreja-Guevara C et al. Review of the novelties presented at the 28th
Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS)
(I). Rev Neurol. 2013 Sep 1;57(5):217-29
Fernández Ó, Arroyo-González R, Rodríguez-Antigüedad A, García-Merino JA, Comabella M, Villar
LM, Izquierdo G, Tintoré M, Oreja-Guevara C, Álvarez-Cermeño JC, Meca-Lallana JE, Prieto JM,
Ramió-Torrentà L, Martínez-Yélamos S, Montalban X. Biomarkers in multiple sclerosis. Rev Neurol.
2013 Apr 1;56(7):375-90.
Oreja-Guevara C, González-Segura D, Vila C. Spasticity in multiple sclerosis: results of a patient
survey. Int J Neurosci. 2013 Jun;123(6):400-8
16/11/14
© European Union, 2002-2014 | http://europass.cedefop.europa.eu
Page 3 / 8
Curriculum Vitae
Celia Oreja-Guevara
Iuliano G, Boz C, Cristiano E, Duquette P, Lugaresi A, Oreja-Guevara C, Van Pesch V. Historical
changes of seasonal differences in the frequency of multiple sclerosis clinical attacks: a multicenter
study. J Neurol. 2012 Dec 21.
Trojano M, Lucchese G, Graziano G, Taylor BV, Simpson S Jr, Lepore V, Grand'maison F, Duquette P,
Izquierdo G, Grammond P, Amato MP, Bergamaschi R, Giuliani G, Boz C, Hupperts R, Van Pesch V,
Lechner-Scott J, Cristiano E, Fiol M, Oreja-Guevara C, Saladino ML, Verheul F, Slee M, Paolicelli D,
Tortorella C, D'Onghia M, Iaffaldano P, Direnzo V, Butzkueven H; MSBase Study Group and the New
Zealand MS Prevalence Study Group. Geographical Variations in Sex Ratio Trends over Time in
Multiple Sclerosis. PLoS One. 2012;7(10):e48078
Oreja-Guevara C. [Treatment of spasticity in multiple sclerosis: new perspectives regarding the use of
cannabinoids]. Rev Neurol. 2012 Oct 1;55(7):421-30.
Oreja-Guevara C, Ramos-Cejudo J, Stark Aroeira L, Chamorro B, Diez-Tejedor E. TH1/TH2 Cytokine
profile in relapsing-remitting multiple sclerosis patients treated with Glatiramer acetate or Natalizumab.
BMC Neurol. 2012 Sep 18;12(1):95.
Carmen Arnal-Garcia , M.Rosa García-Montero , Ignacio Málaga ,Jorge Millán-Pascual , Pedro OlivaNacarino, Lluís Ramió-Torrentà, Celia Oreja-Guevara. Natalizumab use in pediatric patients with
relapsing-remitting multiple sclerosis. Eur J Paed Neurol 2012 Sep 26. pii: S1090-3798(12)00196-1
Fox RJ, Miller DH, Phillips JT, Hutchinson M, Havrdova E, Kita M, Yang M,bRaghupathi K, Novas M,
Sweetser MT, Viglietta V, Dawson KT; CONFIRM Study Investigators. Placebo-controlled phase 3
study of oral BG-12 or glatiramer in multiple sclerosis. N Engl J Med. 2012 Sep 20;367(12):1087-97.
Rieckmann P, Boyko A, Centonze D, Coles A, Elovaara I, Havrdova E, Hommes O, Lelorier J, Morrow
SA, Oreja-Guevara C, Rijke N, Schippling S. Future MS care: a consensus statement of the MS in the
21st Century Steering Group. J Neurol. 2012 Aug 31
Meyniel C, Spelman T, Jokubaitis VG, Trojano M, Izquierdo G, Grand'maison F, Oreja-Guevara C,
Boz C, Lugaresi A, Girard M, Grammond P, Iuliano G, Fiol M, Cabrera-Gomez JA, FernandezBolanos R, Giuliani G, Lechner-Scott J, Cristiano E, Herbert J, Petkovska-Boskova T, Bergamaschi R,
van Pesch V, Moore F, Vella N, Slee M, Santiago V, Barnett M, Havrdova E, Young C, Sirbu CA,
Tanner M, Rutherford M, Butzkueven H; on behalf of the MSBasis Study Group. Country, Sex,
EDSS Change and Therapy Choice Independently Predict Treatment Discontinuation in
Multiple Sclerosis and Clinically Isolated Syndrome. PLoS One. 2012;7(6):e38661
Fernandez O, Alvarez-Cermeno JC, Arroyo-Gonzalez R, Brieva L, Calles-HernandezMC, CasanovaEstruch B, Comabella M, de Las Heras V, Garcia-Merino JA,Hernandez-Perez MA, Izquierdo G,
Meca-Lallana JE, Munoz-Garcia D, Olascoaga J,Oreja-Guevara C, Prieto JM, Ramio-Torrenta L,
Rodriguez-Antiguedad A,Romero-Pinel L, Sanchez F, Tellez N, Tintore M, Montalban X, Grupo PostEctrims GP. Review of the novelties presented at the 27th Congress of the European Committee for
Treatment and Research in Multiple Sclerosis (ECTRIMS) (II). Rev Neurol. 2012 Jun 16;54(12):734749
Oreja-Guevara C. Clinical efficacy and effectiveness of Sativex, a combined cannabinoid medicine, in
multiple sclerosis-related spasticity. Expert Rev Neurother 2012; 12(4s), 3-8
Oreja-Guevara C, Noval S,Alvarez-Linera J, Gabaldón L, Manzano B, Chamorro, B, Diez-Tejedor E.
Clinically isolated syndromes suggestive of multiple sclerosis: an optical coherence tomography study.
PloS One 2012;7(3): e33907
Meca-Lallana JE, Balseiro JJ, Lacruz F, Guijarro C, Sanchez O, Cano A, Costa-Frossard L,
Hernandez-Clares R, Sanchez-de la Rosa R; Escala Study Group. Spasticity improvement in patients
with relapsing-remitting multiple sclerosis switching from interferon-ß to glatiramer acetate: the Escala
Study. J Neurol Sci. 2012 Apr 15;315(1-2):123-8
Fernandez O, Alvarez-Cermeno JC, Arroyo-Gonzalez R, Brieva L, Calles-Hernandez MC, CasanovaEstruch B, Comabella M, de Las Heras V, Garcia-Merino JA, Hernandez-Perez MA, Izquierdo G,
Meca-Lallana JE, Munoz-Garcia D, Olascoaga J, Oreja-Guevara C, Prieto JM, Ramio-Torrenta L,
Rodriguez-Antiguedad A, Romero-Pinel L, Sanchez F, Tellez N, Tintore M, Montalban X, Grupo PostEctrims GP. Review of the novelties presented at the 27th Congress of the European
Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) (I). Rev Neurol. 2012 Jun
1;54(11):677-691
Kister I, Chamot E, Cutter G, Bacon TE, Jokubaitis VG, Hughes SE, Gray OM, Trojano M, Izquierdo
G, Grand'maison F, Duquette P, Lugaresi A, Grammond P, Boz C, Hupperts R, Petersen T, Giuliani G,
Oreja-Guevara C, Iuliano G, Lechner-Scott J, Bergamaschi R, Rio ME, Verheul F, Fiol M, Van Pesch
V, Slee M, Butzkueven H, Herbert J; with the MSBase Investigators. Increasing age at disability
milestones among MS patients in the MSBase Registry. J Neurol Sci. 2012 Jul 15;318(1-2):94-9
Lugaresi A, Ziemssen T, Oreja-Guevara C, Thomas D, Verdun E. Improving patient-physician
16/11/14
© European Union, 2002-2014 | http://europass.cedefop.europa.eu
Page 4 / 8
Curriculum Vitae
Celia Oreja-Guevara
dialog:commentary on the results of the MS Choices survey. Patient Preference and Adherence 2012,
6:143-152
Fernández O, Oreja-Guevara C, Arroyo R, Izquierdo G, Pérez JL, Montalban X. Natalizumab
treatment of multiple sclerosis in Spain: results of an extensive observational study. J Neurol. 2012
Jan 31
Hughes S, Spelman T, Trojano M, Lugaresi A, Izquierdo G, Grand'maison F, Duquette P, Girard M,
Grammond P, Oreja-Guevara C, Hupperts R, Boz C, Bergamaschi R, Giuliani G, Rio ME, LechnerScott J, van Pesch V, Iuliano G, Fiol M, Verheul F, Barnett M, Slee M, Herbert J, Kister I, Vella N,
Moore F, Petkovska-Boskova T, Shaygannejad V, Jokubaitis V, McDonnell G, Hawkins S, Kee F, Gray
O, Butzkueven H; on behalf of the MSBase Study Group. The Kurtzke EDSS rank stability increases
4 years after the onset of multiple sclerosis: results from the MSBase Registry. J Neurol Neurosurg
Psychiatry. 2012 Mar;83(3):305-310.
Lechner-Scott J, Spencer B, de Malmanche T, Attia J, Fitzgerald M, Trojano M, Grand'maison F,
Antonio C Gomez J, Izquierdo G, Duquette P, Girard M, Grammond P, Oreja-Guevara C, Hupperts R,
Bergamaschi R, Boz C, Giuliani G, Pesch VV, Iuliano G, Fiol M, Cristiano E, Verheul F,Saladino ML,
Slee M, Barnett M, Deri N,Fletcher S, Vella N, Shaw C, Herbert J, Moore F, Petkovska-Boskova T,
Jokubatis V, Butzkueven H. The frequency of CSF oligoclonal banding in multiple sclerosis increases
with latitude. Mult Scler.2012 Jul;18(7):974-82.
Fernández O, García-Merino JA, Arroyo R, Alvarez-Cermeño JC, Arbizu T, Izquierdo G, Saiz A, J
Olascoaga, Rodríguez-Antigüedad A, Prieto JM, Oreja-Guevara C, Hernández MA, Montalbán X.
Spanish consensus on the use of natalizumab (Tysabri(®)) Neurología 2012 Sep;27(7):432-441
Noval S, Contreras I, Muñoz S, Oreja-Guevara C, Manzano B, Rebolleda G. Optical coherence
tomography in multiple sclerosis and neuromyelitis optica: an update. Mult Scler Int.
2011;2011:472790.
Abraira V, Alvarez-Cermeño JC, Arroyo R, Cámara C, Casanova B, Cubillo S, de Andrés C, Espejo
C, Fernández O, Ferrer J, Figueredo MA, García-Merino A, García-Sánchez MI, García-Trujillo JA,
Gómez M, González-Oria C, Gosis A, Izquierdo G, Jímenez J, López-Trascasa M, Montalbán X,
Moreno MJ, Muñoz D, Nuñez V, Muriel A, Navarro J, Olascoaga J, Oreja-Guevara C, Prada A, Ramil
E, Ramo-Tello C, Rodríguez C, Rodríguez E, Rodríguez-Frías F, Rodríguez-Antigüedad
A, Rodríguez-Molina JJ, Ruiz E, Saiz A, Sarasola E, Simó M, Yagüe J, Villar LM. Utility of oligoclonal
IgG band detection for MS diagnosis in daily clinical practice. J Immunol Methods. 2011 Aug
31;371(1-2):170-3
Symptomatic therapy in multiple sclerosis: a review for a multimodal approach in clinical practice Joao
Carlos Correia de Sa, Laura Airas, Emmanuel Bartholome, Nikolaos Grigoriadis, Heinrich Mattle,
Celia Oreja-Guevara, Jonathan O'Riordan, Finn Sellebjerg, Bruno Stankoff, Karl Vass, Agata
Walczak, Heinz Wiendl, and Bernd C. Kieseier
Ther Adv Neurol Disord.2011;4 139-168
Ramos-Cejudo J., Oreja-Guevara C, Luiz Stark Aroeira L, Rodriguez de Antonio L, Chamorro B, DiezTejedor E. Treatment with Natalizumab in Relapsing-Remitting Multiple Sclerosis patients induces
changes in inflammatory mechanism. J Clin Immunol. 2011 Aug;31(4):623-31
Rodríguez de Rivera FJ, Oreja Guevara C, Sanz Gallego I, San José Valiente B, Santiago Recuerda
A, Gómez Mendieta MA, Arpa J, Díez Tejedor E. Outcome of patients with amyotrophic lateral
sclerosis attending a multidisciplinary care unit. Neurologia. 2011 Oct;26(8):455-60.
Fernandez-Fernandez O, Alvarez-Cermeno JC, Arbizu-Urdiain T, Arroyo-Gonzalez R, Arnal-Garcia C,
Casanova-Estruch B, Calles-Hernandez MC, Coret-Ferrer F, Comabella M, Garcia-Merino JA, de Las
Heras V, Izquierdo G, Meca-Lallana JE, Munoz-Garcia D, Olascoaga J, Oreja-Guevara C, Prieto JM,
Rodriguez-Antiguedad A, Tintore M, Montalban X, Grupo Post-Ectrims GP. [Review of the novelties
presented at the 26th Congress of the European Committee for Treatment and Research in Multiple
Sclerosis (ECTRIMS) (II).]. Rev Neurol. 2011 Mar 1;52(5):289-299
Fernandez-Fernandez O, Alvarez-Cermeno JC, Arbizu-Urdiain T, Arroyo-Gonzalez R, Arnal-Garcia C,
Casanova-Estruch B, Calles-Hernandez MC, Coret-Ferrer F, Comabella-Lopez M, Garcia-Merino JA,
de Las Heras V, Izquierdo G, Meca-Lallana JE, Munoz-Garcia D, Olascoaga J, Oreja-Guevara C,
Prieto JM, Rodriguez-Antiguedad A, Tintore M, Montalban X, Grupo Post-Ectrims GP. [Review of the
novelties presented at the 26th Congress of the European Committee for Treatment and Research in
Multiple Sclerosis (ECTRIMS) (I).]. Rev Neurol. 2011 Feb 16;52(4):227-238.
Merino JJ, Montes ML, Blanco A, Bustos MJ, Oreja-Guevara C, Bayon C, Cuadrado A, Lubrini G,
Cambron I, Munoz A, Cebolla S, Gutierrez-Fernandez M, BernardinobJI, Arribas JR, Fiala M. [HIV-1
neuropathogenesis: therapeutic strategies against neuronal loss induced by gp120/Tat glycoprotein in
the central nervous system.]. Rev Neurol. 2011 Jan 16;52(2):101-111.
Benito-León J, Rivera-Navarro J, Guerrero AL, de Las Heras V, Balseiro J, Rodríguez E, Belló M,
16/11/14
© European Union, 2002-2014 | http://europass.cedefop.europa.eu
Page 5 / 8
Curriculum Vitae
Celia Oreja-Guevara
Martínez-Martín P; caregiver quality of life in multiple sclerosis (CAREQOL-MS) Study Group. The
CAREQOL-MS was a useful instrument to measure caregiver quality of life in multiple sclerosis. J Clin
Epidemiol. 2011 Jun;64(6):675-86.
Jaime Ramos-Cejudo , Celia Oreja-Guevara . El papel de las células Th-17 en la Esclerosis Múltiple.
Revista Española de Esclerosis Múltiple 2010, 14, 5-8
Oreja-Guevara C, Miralles A, García-Caballero J, Noval S, Gabaldón L, Esteban-Vasallo MD, GarcíaMatres MJ, Bayón-Pérez C, Royo A, González A, Hernanz
A, López-Pajares MR, Morante JL, Díez-Tejedor E. Clinical pathways for the care
of multiple sclerosis patients. Neurologia. 2010 Apr;25(3):156-162
Oreja-Guevara C, Noval S, Manzano B, Gabaldón L, Diez-Tejedor E. Optic neuritis, multiple
sclerosis-related or not: structural and functional study. Neurología, 2010:25(2):78-82
Gabaldón Torres L , Aguilar-Amat Prior MJ , Oreja-Guevara C, Diez-Tejedor E Retinopathy and renal
failure in a patient with multiple sclerosis under treatment with beta-interferon. Medicina Clínica 2010
Apr 17;134(11):511
Bermejo PE, Oreja-Guevara C, Diez-Tejedor E. [Pain in multiple sclerosis: prevalence, mechanisms,
types and treatment.]. Rev Neurol. 2010 Jan 16-31;50(2):101-8
C. Oreja-Guevara, P. E. Bermejo, A. Miralles, L. Gabaldón, M. J. Aguilar, E. Díez-Tejedor. Acetato de
glatiramero en pacientes con esclerosis múltiple remitente-recurrente no respondedores al interferón
beta . Neurología 2009;24(7):435-438
Oreja-Guevara C. Neuromarketing. Neurología Supl 2009;5(1):4-7
Rivera-Navarro J, Benito-León J, Oreja-Guevara C, Pardo J, Bowakim Dib W, Orts E, Belló M. Burden
and health-related quality of life of Spanish caregivers of persons with multiple sclerosis. Mult Scler.
2009 Nov;15(11):1347-55
Oreja-Guevara C, Lubrini G. Deterioro cognitivo en esclerosis múltiple. Revista Española de
Esclerosis Múltiple 2009, 12, 9-16
Peña P, Sancho J, Rufo M, Martínez S, Rejas J; LINCE Study Collaborative Group. Driving cost
factors in adult outpatients with refractory epilepsy: a daily clinical practice in clinics of neurology in
Spain. Epilepsy Res. 2009Feb;83(2-3):133-43.
Rufo-Campos M, Sancho-Rieger J, Peña P, Masramon X, Rejas-Gutiérrez J; Grupo de
Colaboradores del Estudio LINCE. [Drug regimens in patients with medication-resistant epilepsy in
neurology and epilepsy outpatient departments in Spain]. Rev Neurol. 2008 Nov 16-30;47(10):517-24.
Celia Oreja-Guevara, Susana Noval. La tomografía de coherencia óptica en la neuritis óptica y en la
esclerosis múltiple. Revista Española de Esclerosis Múltiple 2008, 6, 22-26.
Sancho J, Peña P, Rufo M, Palacios G, Masramon X, Rejas J; LINCE Study Collaborative Group.
Health and non-health care resources use in the management of adult outpatients with drug-resistant
epilepsy in Spain: a cost-of-illness study (LINCE study). Epilepsy Res. 2008 Oct;81(2-3):176-87.
Oreja-Guevara C . Nuevas Técnicas de Resonancia en Esclerosis Múltiple. Timely topics in Medicine,
Neurologia (http://ww2.ttmed.com/esclerosis_múltiple) Diciembre 2007 (Técnicas de
diagnóstico ).Prous Science
C. Oreja-Guevara, D. Caputo, M. P. Sormani, M. Filippi. Alteraciones de la sustancia gris en pacientes
con esclerosis múltiple remitente-recurrente. Revista Española de Esclerosis Múltiple 2006, 1, 5-11.
C. Oreja-Guevara, A. Charyl, D. Caputo, R. Cavarretta, M. P. Sormani, M. Filippi. Magnetization
transfer magnetic resonance imaging and clinical changes in patients with relapsing-remitting multiple
sclerosis.
Archives of Neurology 2006 May; 63(5):736-40.
C. Oreja-Guevara, M. Rovaris, G. Iannucci, P. Valvasina, D. Caputo, R. Cavarretta, M. P. Sormani, P.
Ferrante, G. Comi, M. Filippi. Progressive grey matter damage in patients with relapsing-remitting MS:
A longitudinal difussion tensor MRI study . Archives of Neurology, 2005 Apr;62(4):578-84.
C. Oreja Guevara, R.Kleiser, W. Paulus, Kruse W. R.J. Seitz, K.-P. Hoffmann The role of V5 (hMT+) in
visually guided hand movements: an fMRI study. Eur J Neurosci. 2004 Jun;19(11):3113-20.
W. Kruse, C. Oreja-Guevara, K.-P. Hoffmann. Sehen und Bewegen: ein Feuerwerk der Nervenzellen.
Neurorubin 2003, 27- 30.
J. Liepert, C. Oreja-Guevara, L.G. Cohen, M. Tegenthoff, M. Hallet, J.-P. Malin. Plasticity of cortical
hand muscle representation in patients with hemifacial spasm. Neurosci. Lett. 1999 Sep 3;272(1):3336.
C. Oreja-Guevara, E. Sindern, M. Raulf-Heimsoth, J.-P. Malin. Analysis of lymphocyte subpopulations
16/11/14
© European Union, 2002-2014 | http://europass.cedefop.europa.eu
Page 6 / 8
Curriculum Vitae
Celia Oreja-Guevara
in cerebrospinal fluid and peripheral blood in patients with multiple sclerosis and inflammatory
diseases of the nervous system. Acta Neurol Scand. 1998 Nov; 98(5): 310-313.
E. Sindern, C. Oreja-Guevara, M. Raulf-Heimsoth, J.-P. Malin. A longitudinal study of circulating
lymphocyte subsets in the peripheral blood during the acute stage of Guillain-Barre syndrome. J
Neurol Sci. 1997 Oct 3;151(1):29-34.
C. Oreja Guevara, E. Sindern, M. Raulf-Heimsoth, J.-P. Malin. Analysis of lymphocyte subpopulations
in cerebrospinal fluid and peripheral blood by flow cytometry of patients with multiple sclerosis.
Aktuelle Neurologie, Band 23(1996): S80.
E. Sindern, LM Ossege, C. Oreja, A. Kirov, J.-P. Malin. Klinische Bedeutung hoher Anti-GM1Antikörper bei Patienten mit akutem Guillain-Barré-Syndrom. Aktuelle Neurologie 1995: 22: 136-139.
E. Sindern, LM Ossege, C. Oreja, J.-P Malin. Klinische Wertigkeit von hohen anti-GM1-Antikörpern
bei akut entzündlichen Radikulopathien. Verhandlungen der Deutschen Gesellschaft für Neurologie 8
(1994) 510-11.
Books
Esclerosis múltiple. C. Oreja-Guevara. En: Neurología. Una introducción a la especialidad
Editorial: Eisai. Madrid, 2012.Pag. 47-58 ISBN: 978-84-92987-19-1
Terapia actual de pacientes con esclerosis múltiple. C. Oreja-Guevara. En: Tysem: Tratamiento y
Seguridad de Esclerosis múltiple en 360°. Editorial: Let´s health, Madrid, 2011.Pag. 63-79 ISBN: 97884-614-6791-4
Leucoencefalopatía multifocal progresiva. Otros efectos adversos asociados a natalizumab.
J. Berenguer Berenguer , C. Oreja-Guevara, J. Meca Lallana. En: Tysem: Tratamiento y Seguridad de
Esclerosis múltiple en 360°. Editorial: Let´s health. Madrid, 2011 Pag. 181-225 ISBN: 978-84-6146791-4
Enfermedades desmielinizantes. Oscar Fernández, Celia Oreja-Guevara et al. Investigación de
enfermedades neurológicas en España. Documento de consenso sobre estrategias y prioridades.
Editor: Sociedad Española de Neurología, 2010. Pág. 61-70. ISBN 978-84-7989-641-6
Biomarcadores. M. Comabella, C. Oreja Guevara. En : Esclerosis Múltiple. Editorial Marge.
Barcelona, 2010. Pag. 361-373 ISBN: 978-84-92442-93-5
Episodios desmielinizantes de etiología desconocida. Oreja Guevara C. En: Casos exepcionales en
Neurología. Editor: Vivancos Matellano F. Madrid, 2009. Pág. 80-86. ISBN 978-84-7989-562-4
Projects
Neurogenesis in progressive forms of Multiple sclerosis (FIS 020107) 2013-2014
Efficacy of pschychotherapeutic treatment of mindfulness in patients with Multiple Sclerosis Ayuda
Fundación Salud 2000 de Investigación en Enfermedades Neurodegenerativas. 2013-2014.
Magnetic Resonance Imaging (MRI) and Optical Coherence Tomography (OCT) study in RRMS
patients treated with Fingolimod. Third Party. 2013-2016
Study of cytoquines and regulatory cells in patients with Multiple Sclerosis . 2008-2012
FUTURA SEN guideline study by Spanish neurologists in the treatment of patients with multiple
sclerosis. 2010-2012
Diffusion tensor study in patients with ALS. Hospital Ruber Internacional 2007-2011
Serial assessment of relapsing-remitting Multiple Sclerosis patients with magnetisation transfer and
acute neurological syndromes using difussion tensor magnetic resonance imaging MRI”. Hospital
Universitario de “San Raffaele” en Milán (Italia), European Neurological Society. 2002-2003
“Plasticity of Spatial Cognition” , Stiftung Volkswagen, University Hospital Bergmannsheil and
University Hospital Düsseldorf ( Germany) 2001-2004
Memberships
Chairman of the demyelinating diseases group of the Spanish Society of Neurology (2009-2012)
Chairman of the demyelinating diseases group of the Society of Neurology of Madrid (2005-present)
Chairman of the neuroimaging group of the Spanish Society of Neurology (2013-present)
Board Member of the Society of Neurology of Madrid (2004-2010)
Board Member of the educational advisory comittee of the Spanish Neurological Society (2005-2008)
Board Member of the research Group of Multiple Sclerosis of the University of Bochum, Germany
(1995-2001)
16/11/14
© European Union, 2002-2014 | http://europass.cedefop.europa.eu
Page 7 / 8
Curriculum Vitae
Celia Oreja-Guevara
Member of the Scientist Panel on Multiple Sclerosis and other Demyelinating Diseases of EFNS
(2010-present)
Member of ECTRIMS Comittee (2011-present)
Member of the spanish network of multiple sclerosis (REEM) (2009-present)
Member of Scientific Comittee of EAN ( European Academy of Neurology) (2014-present)
Other Relevant Information
Scientific Awards
European Federation of Neurological Societies (EFNS) – Award for the best free presentation (short
comunications, posters) in Multiple Sclerosis (2012)
Neurological Society of Madrid – Award for the best oral comunication (2011)
Spanish Neurological Society -Award for the best publication (2010)
Neurological Society of Madrid – Award for the best poster (2009)
Neurological Society of Madrid – Award for the best oral comunication (2008)
Spanish Neurological Society -Award for the best publication (2006)
“Neurólogos para el futuro”- Award (Spanish Neurological Society, 2004)
JOURNALS
Editorial Board Member of Neurologia (journal of Spanish Neurological Society) (2005-2008)
Editorial Board Member of Esclerosis Múltiple (spanish journal of MS) ( 2004- present)
Editorial Board Member of Neuroinmunología (spanish journal of Neuroimmunology) ( 2010- present)
Journal Editor
Academic Editor of Plos One
Journal Reviewer
Plos One
Neurology
Journal of Neuroinflammation
Therapeutic Advances in Neurological Disorders
Journal of Immunological Methods
Expert Review of Pharmacoeconomics& Outcomes Research
Neurology International
JNNP
Revista de Neurología
Neurología
16/11/14
© European Union, 2002-2014 | http://europass.cedefop.europa.eu
Page 8 / 8

Download Report